白云山(00874)：白云山制药总厂获国家药监局核准签发关于骨化三醇软胶囊的《药品补充申请批准通知书》

智通财经04-01

智通财经APP讯，白云山(00874)发布公告，近日，广州白云山医药集团股份有限公司(以下简称“本公司”)分公司广州白云山医药集团股份有限公司白云山制药总厂(以下简称 “白云山制药总厂”)收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于骨化三醇软胶囊的《药品补充申请批准通知书》。骨化三醇软胶囊的适应症：1、绝经后骨质疏松;2、慢性肾功能衰竭,尤其是接受血液透析患者的肾性骨营养不良症;3...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2624597874?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-01 18:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624597874","market":"us","top_or_hot":-1,"title":"白云山(00874)：白云山制药总厂获国家药监局核准签发关于骨化三醇软胶囊的《药品补充申请批准通知书》","media":"智通财经","content":"<div>\n<p>智通财经APP讯，白云山(00874)发布公告，近日，广州白云山医药集团股份有限公司(以下简称“本公司”)分公司广州白云山医药集团股份有限公司白云山制药总厂(以下简称 “白云山制药总厂”)收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于骨化三醇软胶囊的《药品补充申请批准通知书》。骨化三醇软胶囊的适应症：1、绝经后骨质疏松;2、慢性肾功能衰竭,尤其是接受血液透析患者的肾性骨营养不良症;3...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1424098.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>白云山(00874)：白云山制药总厂获国家药监局核准签发关于骨化三醇软胶囊的《药品补充申请批准通知书》</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n白云山(00874)：白云山制药总厂获国家药监局核准签发关于骨化三醇软胶囊的《药品补充申请批准通知书》\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-01 18:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1424098.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，白云山(00874)发布公告，近日，广州白云山医药集团股份有限公司(以下简称“本公司”)分公司广州白云山医药集团股份有限公司白云山制药总厂(以下简称 “白云山制药总厂”)收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于骨化三醇软胶囊的《药品补充申请批准通知书》。骨化三醇软胶囊的适应症：1、绝经后骨质疏松;2、慢性肾功能衰竭,尤其是接受血液透析患者的肾性骨营养不良症;3...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1424098.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1521","symbol_name":"挪威政府全球养老基金持仓","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1424098.html","article_id":"2624597874","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624597874","pubTimestamp":1775040531,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"2026年2月5日，白云山制药总厂向国家药监局递交药品上市持有人变更申请，于2026年3月4日获得受理。本次获得骨化三醇软胶囊的《药品补充申请批准通知书》，扩充了白云山制药总厂产品布局，有利于增强本公司在内分泌治疗药物市场的竞争优势。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600332":"白云山","BK1521":"挪威政府全球养老基金持仓","BK0096":"民营医院","BK0183":"MSCI概念","BK0188":"融资融券","BK0012":"证金概念","BK0028":"国家队","01477":"欧康维视生物-B","BK1191":"制药","BK0175":"白马股","BK1606":"中医药概念","BK0070":"员工持股","BK1515":"抗疫概念","BK1574":"生物医药B类股","BK0196":"行业龙头","00874":"白云山","BK0239":"医药制造","BK0097":"医药电商","BK1197":"保健护理产品经销商"},"translate_title":"Baiyunshan (00874): Baiyunshan Pharmaceutical General Factory was approved by the State Food and Drug Administration to issue the Notice of Approval of Drug Supplementary Application for Calcitriol Soft Capsules","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600332":1.5,"00874":1.5,"01477":1.5},"content_text":"智通财经APP讯，白云山(00874)发布公告，近日，广州白云山医药集团股份有限公司(以下简称“本公司”)分公司广州白云山医药集团股份有限公司白云山制药总厂(以下简称 “白云山制药总厂”)收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于骨化三醇软胶囊的《药品补充申请批准通知书》。骨化三醇软胶囊的适应症：1、绝经后骨质疏松;2、慢性肾功能衰竭,尤其是接受血液透析患者的肾性骨营养不良症;3、术后甲状旁腺功能低下;4、特发性甲状旁腺功能低下;5、假性甲状旁腺功能低下;6、维生素D依赖性佝偻病;7、低血磷性维生素D抵抗型佝偻病等。骨化三醇软胶囊原研厂家是罗氏制药有限公司，于1992年10月在中国首次获批上市。2026年2月5日，白云山制药总厂向国家药监局递交药品上市持有人变更申请，于2026年3月4日获得受理。目前国内骨化三醇软胶囊的主要生产销售厂家有青岛国信制药有限公司、河南泰丰生物科技有限公司、四川国为制药有限公司等。根据米内网数据，2025 年骨化三醇软胶囊在国内城市、县级公立医院及城市、网上药店的销售额为人民币48359万元。截至本公告日，白云山制药总厂在骨化三醇软胶囊研发项目上已投入研发费用合计约人民币1882.86万元(未经审计)。本次获得骨化三醇软胶囊的《药品补充申请批准通知书》，扩充了白云山制药总厂产品布局，有利于增强本公司在内分泌治疗药物市场的竞争优势。白云山制药总厂将按照相关要求和市场需求开展生产。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624597874","isCrawlerRequest":true}